T173A . Sic1-myc 13 or Sic1 T173A -myc 13 were analyzed by phos-tag phosphate affinity and SDS gel electrophoresis (followed by immunoblot analysis using anti-myc or anti-Sic1-pThr 173 antibodies) in extracts from exponentially growing (0 h) and rapamycin-treated (RAP; 2 h) WT and cdc55∆ strains. The 6 differentially phosphorylated Sic1-myc 13 isoforms are numbered sequentially from 1 to 6 (right side of the panels). Adh1 levels served as loading controls.
Supplementary Figure 4 | The Sic1
T173A allele compromises G 1 arrest in rapamycin-treated cells. (a) FACS analyses were performed in exponentially growing (0 h) and rapamycin-treated (times indicated) WT, sic1 T173A , sic1 S191A , and sic1 T173A/S191A cells. The experiments were performed independently 3 times for each strain (one representative FACS profile is shown in Fig. 2g ) and the quantifications (means ± SD) of the percentage of G 1 cells in the respective populations are presented. (b) Bar graphs show the percentage of G 1 cells in the populations of rapamycin-treated (4 h) strains with the indicated genotypes with error bars indicating the 95% confidence interval. The data points from the 4-h rapamycin treatment were further used to perform an ANOVA analysis, which was followed by a Tukey's post-hoc test to examine the differences for each pair of strains. We found a highly significant difference among the four strains (ANOVA, p-value <0.001). 
